Epithelial Na\(^+\) Channels Are Fully Activated by Furin- and Prostasin-dependent Release of an Inhibitory Peptide from the \(\gamma\)-Subunit

James B. Bruns, Marcelo D. Carattino, Shaohu Sheng, Ahmad B. Maarouf, Ora A. Weisz, Joseph M. Pilewski, Rebecca P. Hughey, and Thomas R. Kleyman

Epithelial sodium channels (ENaC) are expressed in the apical membrane of high resistance Na\(^+\) transporting epithelia and have a key role in regulating extracellular fluid volume and the volume of airway surface liquids. Maturation and activation of ENaC subunits involves furin-dependent cleavage of the ectodomain at two sites in the \(\alpha\) subunit and at a single site within the \(\gamma\) subunit. We now report that the serine protease prostasin further activates ENaC by inducing cleavage of the \(\gamma\) subunit at a site distal to the furin cleavage site. Dual cleavage of the \(\gamma\) subunit is predicted to release a 43-amino acid peptide. Channels with a \(\gamma\) subunit lacking this 43-residue tract have increased activity due to a high open probability. A synthetic peptide corresponding to the fragment cleaved from the \(\gamma\) subunit is a reversible inhibitor of endogenous ENaCs in mouse cortical-collecting duct cells and in primary cultures of human airway epithelial cells. Our results suggest that multiple proteases cleave ENaC \(\gamma\) subunits to fully activate the channel.

Epithelial sodium channels (ENaC)\(^3\) are expressed at the apical plasma membrane of cells lining the distal nephron, airway and alveoli, and distal colon, where they play a key role in the regulation of extracellular fluid volume, blood pressure, and airway surface liquid volume. These channels are composed of three homologous subunits, termed \(\alpha\), \(\beta\), and \(\gamma\). Each subunit has cytosolic amino and carboxyl termini and two membrane-spanning domains separated by a large ectodomain (1–3). The second membrane-spanning domain and the preceding region of each subunit are predicted to form the channel pore (4–7). Proteolysis of ENaC subunit extracellular domains at specific sites has a key role in modulating channel gating (8–10). Maturation of ENaC subunits in Xenopus oocytes, Madin-Darby canine kidney (MDCK) cells, and Chinese hamster ovary cells involves furin-dependent cleavage at two sites in the extracellular loop of the \(\alpha\) subunit and at a single site within the extracellular loop of the \(\gamma\) subunit (8). Channels that lack proteolytic processing exhibit markedly reduced activity and enhanced inhibition by external Na\(^+\), a process referred to as Na\(^+\) self-inhibition (9). ENaC subunit cleavage by furin or exogenous trypsin relieves channels from inhibition by external Na\(^+\) (9, 11). We previously proposed that furin-dependent proteolysis of the \(\alpha\) subunit activates ENaC by dissociating an inhibitory domain (\(\alpha\)Asp-206–Arg-231) from its effector site within the channel complex (10).

Endogenous proteases other than furin likely have a role in the processing and activation of ENaC. A number of serine proteases, referred to as “channel activating proteases,” have been identified that increase ENaC activity when co-expressed with ENaC in heterologous expression systems (12–14). Furthermore, selective serine protease inhibitors that do not block furin, such as aprotinin and bikunin, reduce ENaC activity (14–20). Prostasin is an aprotinin-sensitive “channel activating (serine) protease” that increases ENaC activity when co-expressed in Xenopus oocytes (13–15, 20, 21). Prostasin is also thought to have an important role in activating ENaC in collecting duct and airway epithelial cells (16–19, 22, 23).

Because prostasin has been shown to activate ENaC, and we have recently shown that cleavage of the \(\alpha\) and \(\gamma\) subunits is necessary for “normal” channel gating, we examined whether prostasin cleaves ENaC subunits. We observed that prostasin activates ENaC by inducing cleavage of the \(\gamma\) subunit at a site distal to the previously identified furin cleavage site, resulting in an increased channel open probability. Channels with \(\gamma\) subunits that lack the 43-residue tract between the furin and prostasin cleavage sites also have a high open probability. A 43-mer peptide is putatively released from the \(\gamma\) subunit by furin- and prostasin-dependent cleavage, and a synthetic peptide (\(\gamma\)-43) representing this track is an inhibitor of Na\(^+\) channel activity in cortical collecting duct (CCD) and airway epithelia that express endogenous ENaCs.

**EXPERIMENTAL PROCEDURES**

**Vectors and Cell Culture**—Wild type, carboxyl-terminal, and double epitope-tagged mouse ENaC subunit cDNAs were previously described (24, 25). The \(\gamma\) subunit mutations were gen-

---

\(^{1}\) These authors contributed equally to this work.

\(^{2}\) To whom correspondence should be addressed: Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA 15261. Tel.: 412-383-8949; Fax: 412-383-8956; E-mail: hughey@dom.pitt.edu.

\(^{3}\) The abbreviations used are: ENaC, epithelial Na\(^+\) channel; MDCK, Madin-Darby canine kidney; CCD, cortical collecting duct; \(\gamma\)-43, a synthetic 43 residue peptide derived from the \(\gamma\) subunit; CI, 95% confidence interval.
**ENaC Activation by Prostasin**

Erated in pcDNA3.1 (+) (Invitrogen) using a standard two-step PCR method. A cDNA clone (IMAGE 3600399) encoding full-length mouse prostasin was obtained from Open Biosystems (Huntsville, AL) and subcloned into pcDNA3.1 (+).

MDCK type 1 cells were a gift from Barry M. Gumbiner (Memorial Sloan-Kettering Cancer Center, New York) and were cultured as previously described (26). Cortical collecting duct (CCDs) cells (mpkCCDcl4) cells were a gift from Alain Vandewalle (INSERM, Paris, France) and were cultured as previously described (27). Human airway epithelial cells were isolated and cultured as described (28).

**Transient Transfection and Immunoblot Analysis of MDCK Cells**—MDCK cells were transiently transfected with mouse ENaC cDNAs using Lipofectamine 2000 as described by the manufacturer (Invitrogen). The α and β subunits were carboxy-terminal epitope-tagged with Myc and FLAG, respectively. The γ subunit (wild type or mutant) had amino-terminal hemagglutinin and carboxy-terminal V5 epitope tags. Where indicated, mouse prostasin cDNA was co-transfected. The total amount of DNA transfected was held constant by co-transfection of a green fluorescent protein plasmid. Twenty-four hours post-transfection, cells were lysed, and the ENaC-mediated currents were measured.

**Biotinylation of Cell-surface Proteins in Xenopus Oocytes**—Biotinylation was performed essentially as described by Harris et al. (29). All steps were performed on ice using ice-cold solutions. Twenty-four hours post-injection, oocytes (20–40 per group) were placed in an ice-cold modified Barth’s saline (MBS; 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 15 mM HEPES, 0.3 mM Ca(NO3)2, 0.41 mM CaCl2, and 0.82 mM MgSO4, pH 7.4) lacking antibiotics. After a 30-min incubation, oocytes were washed 4 times with MBS without antibiotics and two times with biotinylation buffer (10 mM triethanolamine, 150 mM NaCl, 2 mM CaCl2, pH 9.5). Oocytes were then incubated in biotinylation buffer containing 1 mg/ml EZ-link sulfo-NHS-SS-Biotin (Pierce) for 15 min. Excess biotin reagent was quenched by two washes with quench buffer (192 mM glycine added to MBS) followed by a 5-min incubation in quench buffer. After two washes with MBS, oocytes were lysed by repeated pipetting in lysis buffer (1% Triton X-100, 500 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.4) supplemented with 1% (v/v) Protease Inhibitor Mixture III (Pierce). Lysates were centrifuged at 10,000 × g for 10 min, and supernatants were incubated overnight at 4 °C with 50 μl of immunopure immobilized streptavidin beads (Pierce) with end-over-end rotation. Beads were then washed three times with lysis buffer and immunoblotted as previously described (24).

**Functional Expression in Xenopus Oocytes—ENaC expression in Xenopus oocytes and two-electrode voltage clamp were performed as previously reported (10, 30, 31). Wild type α and β along with double-tagged γ mouse ENaC cRNAs (1 ng per subunit) were injected with or without 3 ng of mouse prostasin cRNA. Electrophysiological measurements were performed 24 h post-injection. The difference in measured current at −100 mV in the absence and presence of amiloride (10–20 μM) was used to identify ENaC-mediated currents.**

**Single Channel Studies**—Patch clamp experiments were performed as previously described (32). Single channel currents were acquired at 5 kHz and filtered at 1 kHz by a 4-pole low pass Bessel filter. For display and analysis, single channel currents were further filtered at 100–200 Hz with a Gaussian filter. Single channel experiments in oocytes were performed in the cell-attached configuration of patch clamp with identical bath and pipette solutions containing 110 mM LiCl, 2 mM CaCl2, 1.54 mM KCl, and 10 mM HEPES, pH 7.4. The bath electrode consisted of an Ag-AgCl pellet connected to the bathing solution via an agar bridge made up in 200 mM NaCl. Liquid junction potentials were not corrected. Open probabilities were determined from recordings of at least 6 min in duration at an applied pipette potential of 60 mV. To estimate open probabilities, all point histograms were fit with Gaussian functions using pCLAMP 6 (Axon Instruments, Forster City, CA).

**Peptides**—Peptides were synthesized and high performance liquid chromatography-purified by the peptide synthesis facility of the University of Pittsburgh’s Molecular Medicine Institute. The sequences of the peptides in single letter amino acid code were: γ cleavage product (γ-43), EAGSMRSTWEGTPPRFLNLPIQFVNEENEGKARDFTFTGRKR; scrambled peptide, FKGFGVKEALREILTFWLRFNNTEDSKPLTRANPPSKGGRE. Both peptides were modified by amino-terminal acetylation and carboxy-terminal amidation.

**Short Circuit Current Recordings**—Cells cultured on permeable membrane supports and mounted in modified Costar Ussing chambers were continuously short-circuited by a voltage clamp amplifier (Physiologic Instruments, San Diego, CA) as previously described by Butterworth et al. (33).

**Statistical Analysis**—Data are presented as the mean ± S.E. Significance comparisons between groups were performed with unpaired Student’s t tests unless otherwise indicated. A p value of less than 0.05 was considered statistically different. IC50 data are presented as the mean with a 95% confidence interval (CI) and were estimated from normalized currents plotted as a function of the peptide concentration fitted with the following equation:

\[ y = b + (t - b)/(1 + 10^{(\log IC50 - x)/(n)}) \]

where y is the response variable, x is the log of the concentration of peptide, n is the Hill coefficient, and IC50 is the concentration of peptide that provokes a response half way between base line (b) and maximum response (t). Fitting and statistical comparisons were performed with Sigmaplot 8.02 (SPSS Inc, Chicago, IL), GraphPad 3.0 (GraphPad Software, San Diego, CA), and Clampfit 9.0 (Axon Instruments Inc., Union City, CA).

**RESULTS**

We recently demonstrated that the α subunit of ENaC must be cleaved twice at two furin cleavage consensus sites to activate the channel (8–10). This double cleavage event excises a 26-mer inhibitory peptide (10). The γ subunit is cleaved once by furin at a site that aligns closely to the first α subunit furin site (Fig. 1). Carboxyl-terminal to the single γ subunit furin site is a tetradecaphosphatase (RRKR186) that does not fit the consensus cleavage sequence for furin (34). This sequence may serve as a site for proteolysis by other serine proteases that cleave after basic residues. Prostasin is a serine protease that has been previously shown to activate ENaC when co-expressed in heterologous...
ENaC Activation by Prostasin

ENaCs were co-expressed with prostasin, an additional γ subunit species of 70 kDa was observed, consistent with cleavage at a site carboxyl-terminal to the furin cleavage site. When the RKRK186 tract in the γ subunit was mutated to QQQR186 (γmut), only the full-length and 75 kDa fragments were observed both in the absence and presence of prostasin expression. These data suggest that prostasin induces cleavage of the γ subunit at the RKRK186 tract.

Co-expression of ENaC and prostasin led to a significant, 3-fold increase in whole cell amiloride-sensitive Na⁺ currents in Xenopus oocytes compared with oocytes expressing ENaC alone (Fig. 2B). Expression of channels with the γ subunit R183Q/K184Q/R185Q/K186Q mutation led to a significant 45% reduction in whole cell Na⁺ currents compared with oocytes expressing wild type ENaCs. Furthermore, co-expression of this mutant ENaC with prostasin led to only a modest, but non-significant increase in Na⁺ currents when compared with oocytes expressing the mutant channels alone (p > 0.05). These results suggest that prostasin-induced cleavage at the RKRK186 site plays a major role in prostasin-dependent activation of ENaC.

Previous reports based on a cell surface expression assay in Xenopus oocytes have inferred that prostasin induces activation of ENaC through an increase in single channel open probability (13–15). We examined the open probability of wild type ENaCs expressed in Xenopus oocytes with or without prostasin co-expression. In contrast to the observations of Adachi et al. (20), channel open probability increased 89% from 0.46 ± 0.05 (n = 11) to 0.87 ± 0.04 (n = 7, p < 0.0001) when ENaC was co-expressed with prostasin (Fig. 3). Prostasin co-expression had no effect on unitary currents at an applied pipette potential of +60 mV (0.41 ± 0.01 pA versus 0.39 ± 0.01 pA, p = 0.33).

We have recently reported that cleavage of ENaC at two sites within the α subunit activates the channel by releasing an inhibitory 26-mer peptide (10). We, therefore, sought to determine whether the 43-mer tract in the γ subunit (Glu-144–Lys-186), predicted to be excised after co-expression with prostasin, also functions as an inhibitory domain. We first examined whether the 43-mer tract in the α subunit (Glu-144–Lys-186), predicted to be excised after co-expression with prostasin, also functions as an inhibitory domain. We first examined whether deletion of the 43-mer tract in the γ subunit would enhance channel activity. In addition to removing the tract, Arg-143 within the γ furin site was mutated to Ala to prevent furin-dependent cleavage. This mutant γ143A,Δ144–186 (γR/ΔA) systems (13–15, 20). Previous studies suggest that a tetra-basic (or dibasic) tract could serve as a substrate for prostasin cleavage (35). We, therefore, examined whether co-expression of ENaC and prostasin altered proteolysis of the γ subunit. ENaCs were expressed in MDCK cells with the γ subunit bearing a carboxyl-terminal V5 epitope tag. After cell lysis, immunoprecipitation, and subsequent immunoblotting with an anti-V5 antibody, we observed both full-length (93 kDa) and furin-cleaved (75 kDa) γ subunit (Fig. 2A). When
ENaC Activation by Prostasin

![Image](https://example.com/image.png)

**FIGURE 3.** Prostasin increases the open probability of ENaC. Single channel recordings were performed in the cell-attached configuration of patch clamp using oocytes co-expressing wild type ENaC with or without prostasin as described under “Experimental Procedures.” Representative single channel recordings from oocytes expressing wild type channels with [A] or without prostasin [B] are shown. Amplitude histograms are presented at the right side of each recording. C indicates the closed state. C, open probabilities of ENaC estimated from oocytes co-expressing wild type channels with or without prostasin in the same batch of oocytes (n = 7–11, p < 0.0001, unpaired Student’s t-test).

was not cleaved when co-expressed with α and β subunits in MDCK cells (Fig. 4B). However, when this mutant was co-expressed with α and β subunits in oocytes, whole cell Na⁺ currents were 3.7-fold greater than currents recorded in oocytes expressing wild type αβγ (Fig. 4A). At a single channel level, the mutant channel was constitutively active, with an open probability of >0.95, compared with wild type channels that had an open probability of 0.37 ± 0.06 (Fig. 5). Unitary currents were not different between mutant (0.39 ± 0.03 pA) and wild type (0.40 ± 0.01) channels at an applied pipette potential of +60 mV (n = 4, p = 0.75).

Our results suggest that cleavage of the γ subunit by furin and prostasin is required to release an inhibitory domain. If this hypothesis is correct, mutation of the γ furin site to block furin cleavage should prevent prostasin-dependent activation of the channel. Indeed, we observed that αβγR143A, a mutant that lacks furin-dependent proteolysis of the γ subunit (8), was not activated by prostasin when co-expressed in oocytes (Fig. 6).

We next examined whether a synthetic peptide (γ-43), corresponding to the 43-mer tract excised from the γ subunit, inhibited endogenous ENaC in epithelia. When added to the apical chamber of filter grown mouse CCD cells, γ-43 (3 μM) rapidly inhibited short circuit currents (Fig. 7A). Peptide-dependent inhibition of the channel was reversible as the current was restored after washout of γ-43. This peptide inhibited short circuit currents in mouse CCD cells and in primary cultures of human airway cells in a dose-dependent manner, with an IC₅₀ of 3.2 μM (CI, 2.7–3.8 μM) and 2.0 μM (CI, 1.9–2.2 μM), respectively (Fig. 7, B and C) (n = 8–9). In contrast, a minimal effect on short circuit current was observed upon the addition of a control, scrambled peptide. These data suggest that the 43-mer tract excised by furin- and prostasin-dependent proteolysis functions as an endogenous inhibitor of ENaC activity prior to γ subunit cleavage.

We recently reported that the inhibitory 26-mer peptide cleaved from the α subunit does not appear to interact with the amiloride binding site, based on its lack of competition with amiloride (10). To our surprise, the γ-43 peptide significantly increased the IC₅₀ for amiloride block by 60% in CCD cells (Fig. 8). The amiloride IC₅₀ was 431 nM (CI, 339–548 nM) in the presence of 3 μM γ-43 and 270 nM (CI, 238–306 nM) in the absence of γ-43.

The role of prostasin catalytic activity in ENaC activation has recently been called into question. Although the serine protease inhibitor aprotinin abolishes prostasin-induced activation of ENaC in Xenopus oocytes (13–15, 20), mutations within the prostasin putative catalytic triad do not prevent this activation (36). We, therefore, examined whether a catalytic site mutant of prostasin could activate ENaC as well as induce cleavage of the γ subunit. Co-expression of a prostasin mutant S238A (within the catalytic triad) and αβγ in oocytes resulted in a significant increase in whole cell Na⁺ currents compared with Xenopus...
DISCUSSION

We previously reported that ENaC α and γ subunits are processed by the endoprotease furin within their extracellular domains (8). Two extracellular furin cleavage sites are present within the α subunit, and inhibition of furin-dependent processing of the α subunit by mutating either one or both furin cleavage sites led to a profound inhibition of ENaC activity (8–10). Furin-dependent cleavage of the α subunit releases a 26-mer inhibitory peptide (10). We have also shown that the γ subunit is cleaved once by furin. In contrast to the α subunit, prevention of furin-dependent processing of the γ subunit was associated with only a modest reduction in ENaC activity (8).

Our observation that the γ subunit must be cleaved twice to activate ENaC raised the possibility that the γ subunit also must be cleaved twice to fully activate ENaC by releasing a second inhibitory peptide. Because there is only one furin cleavage site in the γ subunit, other proteases might cleave the γ subunit and activate ENaC. Our results suggest that prostasin or a subsequent protease activated by prostasin fulfills this task. Prostasin cleavage occurs immediately after tracts of basic amino acid residues (35). We identified an RKRK186 tract ∼40 residues carboxy-terminal to the furin cleavage site in the γ subunit as a potential prostasin-dependent cleavage site. Several lines of evidence suggest that prostasin is responsible for γ subunit cleavage at this site. Co-expression of ENaC and prostasin in MDCK cells and Xenopus oocytes resulted in the appearance of a second, more rapidly migrating γ subunit cleavage product, consistent with the expected change in mobility upon cleavage.
This second cleavage product was absent when prostasin was co-expressed with a mutant ENaC where the residues in the RKRK186 tract were changed to glutamine. Moreover, when this mutant ENaC was expressed in *Xenopus* oocytes, co-expression of prostasin failed to significantly activate ENaC, whereas this protease enhanced the activity of wild type ENaC (Fig. 2B). The fact that channels with the /H9253 subunit R183Q/K184Q/R185Q/K186Q mutation exhibited lower currents than wild type channels suggests that there may be limited proteolysis of wild type channels at this site in *Xenopus* oocytes in the absence of prostasin co-expression.

If prostasin and furin activate ENaC as a result of two separate cleavage events in the /H9253 subunit that releases a 43-mer inhibitory peptide, we reasoned that channels lacking this tract would exhibit an increase in channel activity. We found that channels lacking both this 43-mer tract and the furin cleavage site in the /H9253 subunit exhibited greatly enhanced activity (Fig. 4A) and an open probability that approached 1.0 (Fig. 5) even though this mutant /H9253 subunit was not cleaved (Fig. 4B). The synthetic 43-mer peptide γ-43 reversibly inhibited endogenous ENaC activation by prostasin.

**FIGURE 7.** A peptide (γ-43) representing the γ cleavage product inhibits transepithelial Na⁺ transport in epithelia endogenously expressing ENaC. A, mouse CCD cells cultured on permeable membrane supports and mounted in a modified Ussing chamber were continuously short-circuited. Transepithelial resistance was monitored by applying a 4-mV bipolar pulse every 60 s. Where indicated, a 43-residue peptide corresponding to the tract Glu-144–Lys-186 of mouse γ ENaC (γ-43) was added to the apical chamber at a final concentration of 3 μM. This led to a marked inhibition of transepithelial Na⁺ transport that was relieved by washout of the peptide. Subsequent application of 20 μM amiloride to the apical chamber confirmed that the short circuit current reflected ENaC-mediated transepithelial Na⁺ transport. Tracing is representative of five experiments. CCD cells (B) or primary cultures of human airway cells (C) cultured and voltage-clamped as above were exposed to increasing concentrations of either γ-43 (filled circles) or a scrambled peptide (open circles). Although the scrambled peptide failed to inhibit amiloride-sensitive short circuit currents, the γ cleavage product inhibited in a dose-dependent manner (n = 8–9). *Iₛ*, short circuit current.

**FIGURE 8.** Effect of the γ-43 peptide on amiloride block of ENaC. Mouse CCD cells cultured on permeable membrane supports and mounted in a modified Ussing chamber were continuously short-circuited by a voltage clamp amplifier (Physiologic Instruments, San Diego, CA). A, dose response curves for amiloride in the presence (open circles) or absence (closed circles) of 3 μM γ-43 peptide. B, amiloride IC₅₀ values in the absence or presence of 3 μM γ-43 peptide (n = 18). *, p < 0.001.

The synthetic 43-mer peptide γ-43 reversibly inhibited endogenous ENaC activation by prostasin.
ENaCs expressed in human airway epithelial cells and in mouse CCD cells with IC_{50} values of ~2–3 μM (Fig. 7). We also reasoned that channels lacking furin processing of the γ subunit (αβγR143A) would not be activated by prostasin due to lack of release of an inhibitory domain. Indeed, this is what we observed (Fig. 6).

Although peptides excised from both the α and γ subunits inhibit ENaCs, they share limited similarity at the primary amino acid level (Fig. 1B). There are a number of other differences between these two inhibitory peptides. The 43-mer γ subunit derived peptide is a relatively potent inhibitor of ENaC expressed in human airway and mouse CCD cells (Fig. 7), in contrast to the 26-mer peptide derived from α subunit cleavage that inhibited ENaC activity in human airway and mouse CCD cells with IC_{50} values of 50–100 μM (10). The α subunit-derived peptide did not alter the IC_{50} of amiloride for ENaC, suggesting that the 26-mer peptide and amiloride interact at distinct sites within ENaC (10). In contrast, the γ subunit-derived peptide γ-43 significantly altered the dose-dependent inhibition of amiloride (Fig. 8). Although the γ-43 peptide and amiloride may interact at common sites within the channel (competitive inhibition), the modest change in the apparent amiloride IC_{50} in the presence of γ-43 peptide is also consistent with amiloride and the γ-43 peptide interacting at distinct sites (non-competitive inhibition). Binding of the peptide to the channel may indirectly affect amiloride binding.

Previous studies demonstrating that the serine protease inhibitor aprotinin abolishes prostasin-induced activation of ENaC in Xenopus oocytes (13–15, 20) are consistent with the possibility that prostasin activates ENaC by cleaving the γ subunit. However, the role of prostasin catalytic activity in ENaC activation has recently been called into question. Serine proteases have three well defined residues, referred to as a catalytic triad, which are required for catalytic activity (37). Andreasen et al. (36) recently reported that prostasin with mutations within its putative catalytic triad activates ENaC when co-expressed in oocytes.

We confirmed that prostasin bearing a mutation of one of the catalytic triad residues (S238A) activates ENaC expressed in oocytes (Fig. 9A). This prostasin mutant did not activate ENaCs with the γ subunit mutation R183Q/K184Q/K185Q/K186Q at the putative prostasin cleavage site (Fig. 9). Surprisingly, channel activation by this mutant prostasin was associated with proteolytic processing of the γ subunit. The more rapidly migrating γ subunit cleavage product (75 kDa) was readily detected when wild type ENaC was co-expressed with the S238A prostasin mutant in oocytes (Fig. 9B), suggesting that this prostasin mutant induces cleavage of the γ subunit at the RRK^{186} site. The catalytic activity of prostasin bearing mutations within the putative catalytic triad has not previously been addressed. However, Carter and Wells (38) have reported that mutations within the catalytic triad of Bacillus amyloliquefaciens subtilisin do not completely eliminate catalytic activity (38). Alternatively, the mutant prostasin as well as wild type prostasin might bind to and suppress endogenous Xenopus protease inhibitors, allowing an endogenous protease to cleave the γ subunit within the RRK^{186} tract.

Our results begin to address the question of why multiple proteases have a role in the activation of ENaC. Furin-dependent cleavage of the α subunit at two sites releases a 26-mer inhibitory peptide (10). However, furin-dependent cleavage of the γ subunit occurs at only one site and is not expected to release the γ subunit inhibitory peptide (8). A second cleavage event mediated by prostasin or perhaps other proteases such as elastase is required to release a γ subunit inhibitory peptide. Harris et al. (29) recently reported that exogenous neutrophil elastase cleaves the γ subunit of rat ENaC expressed at the cell surface of Xenopus oocytes and increases I_{Na} by 5–7-fold.

We propose that multiple proteolytic cleavage events lead to a stepwise activation of ENaC, reflected in a stepwise increase in channel open probability. Channels that lack proteolytic processing have a low open probability (9). Channels that have been cleaved solely by furin exhibit an intermediate open probability, as these are likely the active channels that are observed in Xenopus oocytes at a single channel level (Fig. 3A), where there appears to be limited proteolytic release of the γ subunit inhibitory peptide under basal conditions. In contrast, channels that have released both α subunit and γ subunit inhibitory peptides exhibit a high open probability, as we observed in oocytes co-expressing ENaC and prostasin (Fig. 3B).
ENaC Activation by Prostasin

Previous studies in airway epithelial cells and renal cortical collecting duct cells have shown that nonspecific inhibitors of prostasin, such as aprotinin, bikunin, and protease nexin-1 reduce ENaC activity (14–20, 39). Channel activity can be restored by either removing the inhibitor or by treating cells with extracellular trypsin (16–18). In cultured CCD cells, we have also shown that a furin-specific inhibitor (α1-PDX) dramatically reduced ENaC activity (8). It has been unclear why inhibitors of both prostasin and furin reduce channel activity. We previously reported that two pools of channels are present at the plasma membrane, a pool of channels processed by furin and perhaps other proteases and a second pool of near silent channels that have escaped proteolytic processing (40). We and others have suggested that these non-cleaved channels represent a pool of nearly silent channels and that prostasin or other proteases might activate ENaC by processing these non-cleaved channels at the plasma membrane (40–42). Mechanisms by which prostasin activates ENaC are clearly more complex. In addition to the processing of non-cleaved channels, prostasin-dependent processing of channels has been already cleaved by furin in the biosynthetic pathway further enhances channel activity.

In summary, our results suggest that prostasin activates ENaC by affecting cleavage of the γ subunit and, in concert with furin-dependent cleavage of the γ subunit, releases an inhibitory peptide. In a similar manner, furin-dependent processing within the α subunit at two sites releases an inhibitory peptide. These peptides released from the α and γ subunits may serve as initial templates for developing a new class of peptide based ENaC inhibitors.

Acknowledgments—The mpkCCDc14 cells were a gift from Alain Vandewalle (Paris, France). MDCK cells were a gift from Barry Gumbiner (Memorial Sloan-Kettering Cancer Center, New York).

REFERENCES
1. Snyder, P. M., McDonald, F. J., Stokes, J. B., and Welsh, M. I. (1994) J. Biol. Chem. 269, 24379–24383
2. Renard, S., Lingueglia, E., Voilley, N., Lazdunski, M., and Barbry, P. (1994) J. Biol. Chem. 269, 12981–12986
3. Canessa, C. M., Merillat, A. M., and Rossier, B. C. (1994) Am. J. Physiol. 267, C1682–C1690
4. Schuld, L., Schneeberger, E., Gautschi, I., and Firsov, D. (1997) J. Gen. Physiol. 109, 15–26
5. Snyder, P. M., Olson, D. R., and Bucher, D. B. (1999) J. Biol. Chem. 274, 28484–28490
6. Sheng, S., Li, J., McNulty, K. A., Kieber-Emmons, T., and Kleyman, T. R. (2001) J. Biol. Chem. 276, 1326–1334
7. Sheng, S., McNulty, K. A., Harvey, J. M., and Kleyman, T. R. (2001) J. Biol. Chem. 276, 44091–44098
8. Hugher, R. P., Bruns, J. B., Kinlough, C. L., Harkleroad, K. L., Tong, Q., Carattino, M. D., Johnson, J. P., Stockand, J. D., and Kleyman, T. R. (2004) J. Biol. Chem. 279, 18111–18114
9. Sheng, S., Carattino, M. D., Bruns, J. B., Hugher, R. P., and Kleyman, T. R. (2006) Am. J. Physiol. Renal Physiol. 290, 1488–1496
10. Carattino, M. D., Sheng, S., Bruns, J. B., Pilewski, J. M., Hugher, R. P., and Kleyman, T. R. (2006) J. Biol. Chem. 281, 18901–18907
11. Chraibi, A., and Horisberger, J. D. (2002) J. Gen. Physiol. 120, 133–145
12. Rossier, B. C. (2004) Proc. Am. Thorac. Soc. 1, 4–9
13. Vuagniaux, G., Vallet, V., Jaeger, N. F., Hummler, E., and Rossier, B. C. (2002) J. Gen. Physiol. 120, 191–201
14. Vallet, V., Chraibi, A., Gaeggeler, H. P., Horisberger, J. D., and Rossier, B. C. (1997) Nature 389, 607–610
15. Vuagniaux, G., Vallet, V., Jaeger, N. F., Pfister, C., Bens, M., Farman, N., Courtois-Courty, N., Vandewalle, A., Rossier, B. C., and Hummler, E. (2000) J. Am. Soc. Nephrol. 11, 828–834
16. Liu, L., Hering-Smith, K. S., Schiro, F. R., and Hamm, L. L. (2002) Hypertension 39, 860–864
17. Adebamiro, A., Cheng, Y., Johnson, J. P., and Bridges, R. J. (2005) J. Gen. Physiol. 126, 339–352
18. Bridges, R. J., Newton, B. B., Pilewski, J. M., Devor, D. C., Poll, C. T., and Hall, R. L. (2001) Am. J. Physiol. Lung Cell. Mol. Physiol. 281, 16–23
19. Myerburg, M. M., Butterworth, M. B., McKenna, E. E., Peters, K. W., Frizzell, R. A., Kleyman, T. R., and Pilewski, J. M. (2006) J. Biol. Chem. 281, 27942–27949
20. Adachi, M., Kitamura, K., Miyoshi, T., Narikiyo, T., Iwashita, K., Shiraishi, N., Nonoguchi, H., and Tomita, K. (2001) Am. J. Physiol. 12, 1114–1121
21. Vallet, V., Pfister, C., Loffing, I., and Rossier, B. C. (2002) Am. J. Physiol. 13, 588–594
22. Narikiyo, T., Kitamura, K., Adachi, M., Miyoshi, T., Iwashita, K., Shiraishi, N., Nonoguchi, H., Chen, L. M., Chai, K. X., Chao, J., and Tomita, K. (2002) J. Clin. Invest. 109, 401–408
23. Iwashita, K., Kitamura, K., Narikiyo, T., Adachi, M., Shiraishi, N., Miyoshi, T., Nagano, J., Tuyen, D. G., Nonoguchi, H., and Tomita, K. (2003) Am. J. Physiol. 14, 11–16
24. Hughery, R. P., Mueller, G. M., Bruns, J. B., Kinlough, C. L., Poland, P. A., Harkleroad, K. L., Carattino, M. D., and Kleyman, T. R. (2003) J. Biol. Chem. 278, 37073–37082
25. Ahn, Y. J., Brooker, D. R., Kosari, F., Harte, B. J., Li, J., Mackler, S. A., and Kleyman, T. R. (1999) Am. J. Physiol. 277, F121–F129
26. Lavelle, J. P., Negrete, H. O., Poland, P. A., Kinlough, C. L., Meyers, S. D., Hughery, R. P., and Zeidel, M. L. (1999) J. Am. Soc. Nephrol. 10, 923–934
27. Devor, D. C., Bridges, R. J., and Pilewski, J. M. (2000) Am. J. Physiol. Cell Physiol. 279, 461–479
28. Hahrs, M., Firsov, D., Vuagniaux, G., Stutts, M. J., and Rossier, B. C. (2007) J. Biol. Chem. 282, 58–64
29. Bruns, J. B., Hu, B., Ahn, Y. J., Sheng, S., Hughery, R. P., and Kleyman, T. R. (2003) Am. J. Physiol. Renal Physiol. 285, 600–609
30. Carattino, M. D., Hill, W. G., and Kleyman, T. R. (2003) J. Biol. Chem. 278, 36202–36213
31. Carattino, M. D., Sheng, S., and Kleyman, T. R. (2005) J. Biol. Chem. 280, 4393–4401
32. Butterworth, M. B., Edinger, R. S., Johnson, J. P., and Frizzell, R. A. (2005) J. Gen. Physiol. 125, 81–101
33. Rockwell, N. C., Krysan, D. J., Komiyama, T., and Fuller, R. S. (2002) Chem. Rev. 102, 4525–4548
34. Shipway, A., Danahay, H., Williams, J. A., Tully, D. C., Backes, B. J., and Fuller, R. S. (2004) J. Biol. Chem. 279, 347–352
35. Rockwell, N. C., Krysan, D. J., Komiyama, T., and Fuller, R. S. (2002) Chem. Rev. 102, 4525–4548